Author Archives: Scalper1

Apple Offers Possible Clue To Apple Car In SEC Filing

Apple ( AAPL ) may have tipped its hand about investments in developing an electric car in its latest 10-Q filing with the U.S. Securities and Exchange Commission, UBS analyst Steven Milunovich said Thursday. Apple reported that “other off-balance sheet obligations” were up over 75% year over year to a record high near $12 billion. “Our hunch is that this increase in part reflects spending for the Apple car or Project Titan,” Milunovich said in a research note. “Apple has been buying and leasing buildings with Greek god names and dedicated spaces for ‘tire changing,’ ‘lube stations,’ and ‘wheel balancer.’” The Apple Car has been the subject of much talk over the past few weeks after the Silicon Valley Business Journal reported that Apple had been purchasing and leasing a variety of buildings in Sunnyvale and San Jose, Calif., clearly meant for automotive research and development, Milunovich said. Apple recently hired Chris Porritt , former Tesla Motors ( TSLA ) vice president of vehicle engineering and former Aston Martin chief engineer, to work on its Project Titan electric car venture, according to media reports. Other explanations for the increase in off-balance sheet obligations include costs associated with Apple’s new campus in Cupertino, Calif., and expansion of data centers to support service offerings, he said. Milunovich reiterated his buy rating on Apple stock with a 12-month price target of 120. Apple shares fell 3.1% to 94.83 on Thursday after billionaire investor Carl Icahn told CNBC that he had sold his stake in Apple over concerns about the company’s prospects in China. At one point, Icahn owned 53 million shares of Apple, or nearly 1% of the company. “We no longer have a position in Apple,” Icahn said in an interview on CNBC. RELATED: 5 Key Takeaways From Apple’s Unsettling Q2 Earnings Report Apple Car Will Look Like Egg On Wheels If Motor Trend Design Right

LinkedIn Shatters Q1 Earnings, Stock Rallies In After-Hours Trading

Deep amid a business transition, LinkedIn ( LNKD ) late Thursday reported first-quarter earnings and sales that beat Wall Street consensus expectations, as did its Q2 earnings and sales guidance. LinkedIn stock at first jumped 15% in after-hours trading, after the earnings release, but later was up 8%. In the regular session, LinkedIn stock rose 3.5%, to 123.01. Fellow social network Facebook ( FB ) rose 7.2% Thursday after that company late Wednesday posted Q1 results and gave guidance that beat analyst views. Thursday’s reaction is in marked contrast to three months ago, when LinkedIn posted a Q4 beat but gave guidance that fell well short of expectations, sending shares plummeting 44% the next day, to 108. Shares have been slowly recovering. LinkedIn reported Q1 revenue of $860.7 million, up 35% year over year and beating the consensus of $828.5 million. It reported earnings per share minus items of 74 cents, up 30% and beating the consensus of 60 cents, as polled by Thomson Reuters. For Q2, LinkedIn sees sales of $885 million to $890 million, up 25% at the midpoint and above the $886 million analysts had modeled. The company expects EPS ex items of 74 cents to 77 cents, up at least 35% from 55 cents in Q2 2015 and above the 71 cents analysts had modeled. LinkedIn provided full-year sales guidance of $3.65 billion to $3.7 billion, with the midpoint in line with analyst consensus of $3.67 billion. Non-GAAP EPS is expected to be between $3.30 and $3.40, above the consensus of $3.19. LinkedIn, which provides most of its services to members at no cost, generates revenue from three business segments. Revenue from Talent Solutions, which gets fees from companies and headhunters seeking hires, rose 41% year-over-year to $558 million. Revenue from Marketing Solutions, which sells ads, increased 29% to $154 million. Revenue from Premium Subscriptions increased 22% to $149 million. LinkedIn said it ended the quarter with 433 million members, up 19% and its strongest net additions since the beginning of 2014, the company said. Unique visiting members rose 9% to an average of 106 million members a month, and member page views grew 34%. Page views per unique visiting member hit an all-time high in Q1, with 23% year-over-year growth, LinkedIn said. “Q1 marked the first full quarter for our new mobile flagship experience, and we are pleased with the performance thus far,” said CEO Jeff Weiner in the company’s earnings conference call. “Members are engaging at record levels with the more relevant and comprehensive feed.” The weak Q1 guidance three months ago caused analysts to slash their estimates, partly on an apparent deceleration of the Talent Solutions segment. At the time, LinkedIn said a reshuffling of product strategy would impact short-term revenue growth in favor of the long term. Then, the company also said it would shutter a business called Lead Accelerator. That decision cut the company’s 2016 revenue forecast by $50 million. The Lead Accelerator business had been created out of LinkedIn’s $175 million acquisition of Bizo in July 2014. The technology focuses on boosting the ability of marketers to target prospects and had been considered a high-growth opportunity. LinkedIn said the manpower needed to boost Lead Accelerator was not worth the time and effort, and that it was “a higher-than-anticipated demand on resources.” The move did not go over well with analysts, with one calling it a “gigantic mistake.” But that move along with other strategy shifts have set the stage for future growth, Weiner said. He said LinkedIn strengthened its core Recruiter product while also laying the groundwork for the rollout of a number of emerging growth drivers. Its Recruiter platform, within the Talent Solutions group, “is the foundation of our long-term growth strategy,” Weiner said, adding that recruiters are experiencing “greater success” with the new product. The company said hiring revenue contributed$502 million in revenue in Q1, up 27% from Q1 2015.

Amgen Legacy Drugs Drive Q1 Beat; Gilead Hep C Juggernaut Stumbles

Big biotech Amgen ( AMGN ) beat Wall Street’s Q1 estimates and raised guidance Thursday after the close, though its stock went sideways in after-hours trading. Its peer Gilead Sciences ( GILD ), however, was down sharply after a weak quarter. Amgen reported adjusted earnings of $2.90 a share, up 17% from the year-earlier quarter and 30 cents ahead of analysts’ consensus, according to Thomson Reuters. Revenue increased 10% to $5.53 billion, more than $200 million above consensus. The company lifted its full-year guidance, though not by quite as much as the Q1 beat. Its EPS range is now $10.85 to $11.20, up from $10.60 to $11. The revenue guide is $22.2 billion to $22.6 billion, vs. $22 billion to $22.5 billion. Last year, Amgen made $10.38 in EPS on $21.66 billion in revenue. Amgen’s best-selling drug Enbrel, for rheumatoid arthritis, beat expectations by growing 24% to $1.39 billion, almost $140 million above consensus, according to Evercore ISI. Its second-biggest drug Neulasta, for neutropenia, modestly beat estimates by gaining 4% to $1.18 billion. On the other hand, some of Amgen’s newer drugs came up short. Cancer drug Kyprolis grew 43% but was still $19 million shy of consensus with $154 million in sales, while newly launched cholesterol drug Repatha continued its underperformance with a $16 million take. Gilead Takes A Hit In Hep C Gilead, meanwhile, reported earnings of $3.03 a share excluding one-time items, up 3% from last year’s Q1 and 12 cents below Wall Street’s average estimate. Revenue rose 2.6% to $7.79 billion, about $325 million below consensus. Gilead nonetheless made no change to its full-year guidance, calling for $30 billion to $31 billion in product sales and 88% to 90% gross margin. Gilead’s blockbuster hepatitis C drugs Harvoni and Sovaldi accounted for most of the shortfall, though for opposite reasons: Harvoni missed badly in the U.S. but outperformed abroad, while Sovaldi did the opposite. Earlier in the day, AbbVie ( ABBV ) reported that Harvoni’s chief competitor Viekira also came up short of consensus, which the company attributed to Merck ‘s ( MRK ) unexpectedly aggressive pricing of recently launched rival Zepatier. (Merck will report its Q1 on May 5.) The quarter also brought a screeching halt to Gilead’s two-year stretch of double- or triple-digit sales and profit growth, starting with the Dec. 2013 launch of Sovaldi. Analysts expect growth will totally flatten unless the company makes a transformative acquisition. Gilead stock was down more than 6% after hours Thursday, after it closed the regular session down 3.7%, at 97.